Ambalaj Validasyonu – ISO 11607

What Is Packaging Validation — ISO 11607?

Packaging validation is the set of studies proving a sterile medical device's packaging maintains the sterile barrier until the point of use. ISO 11607-1 defines the packaging system's requirements, and ISO 11607-2 the validation of the packaging (sealing) process.

Purpose of Packaging Validation — ISO 11607

The purpose is to assure the product stays sterile through transport, storage and shelf life after sterilisation. If the sterile barrier fails, sterilisation itself becomes meaningless.

Which Products Is Packaging Validation — ISO 11607 Applied To?

Sterile single-use device packaging
Tyvek/film pouches and blister packs
Paper-film bags
Surgical set packaging
Implant packaging

In Which Sectors Is Packaging Validation — ISO 11607 Used?

Medical DevicePharmaceuticalsHealthcareBiotechnology

Standards Related to Packaging Validation — ISO 11607

ISO 11607end product sterile barrier packaging test

Packaging Validation — ISO 11607 Conditions

Integrity tests: Dye penetration, bubble test, visual inspection
Seal strength: Peel strength per ASTM F88
Transport simulation: Vibration, drop and pressure sequence per ASTM D4169
Ageing: Real-time and accelerated ageing (ASTM F1980)

Equipment for Packaging Validation — ISO 11607

Tensile tester and seal strength grips
Leak-tightness test rig (bubble and dye penetration)
Vibration table and drop test rig
Climate and ageing chambers
Seal imaging and inspection equipment

Sample Requirements for Packaging Validation — ISO 11607

Specimens must be produced by the packaging process being validated.
The worst-case configuration (heaviest product, sharpest geometry) must be selected.
The number of specimens must be based on statistical justification.
Sterilised and non-sterilised specimens must be assessed separately.
A separate specimen set must be reserved for the ageing study.

Duration of Packaging Validation — ISO 11607

Integrity and seal strength tests are completed within days. Transport simulation takes a few days. Real-time ageing runs for the declared shelf life; accelerated ageing gives preliminary evidence but must be supported by real-time data.

Packaging Validation — ISO 11607 Procedure

1The packaging system and worst-case configuration are defined.
2Packaging process parameters (temperature, pressure, time) are set and IQ/OQ/PQ are carried out.
3Specimens are sterilised.
4Integrity and seal strength tests are applied.
5Transport simulation is performed per ASTM D4169.
6Integrity tests are repeated after simulation.
7Tests are repeated at the end of accelerated and real-time ageing.

Packaging Validation — ISO 11607 Acceptance Criteria

The acceptance criterion is selected from the relevant section of the standard according to the device's contact type (surface, externally communicating, implant), contact duration and intended use. The assessment relies not on a single test result but on the biological evaluation plan carried out under ISO 10993-1; this page therefore gives no fixed limit.

Evaluation of Results

The assessment relies on showing the packaging maintains its sterile barrier after transport and ageing too. The acceptance range for seal strength comes from the manufacturer's process validation: it must be strong enough not to leak yet controlled enough to open aseptically.

Packaging Validation — ISO 11607 Report

Device identification, model and lot number, if any
Device contact type, duration and intended use
Standard and section applied
Extraction or sample preparation conditions
Cell line, test system or test rig used
Controls and their results
Observations, measurement results and assessment
A statement that the result applies only to the specimen submitted for testing

Accreditation

EUROLAB holds internationally recognised accreditation obtained from accreditation bodies party to the IAF and ILAC multilateral recognition arrangements, under ISO/IEC 17025 for laboratory testing, ISO/IEC 17020 for inspection and surveillance, and ISO/IEC 17021-1 and ISO/IEC 17065 for system and product certification. This chain ensures the reports and certificates issued are accepted worldwide.

Whether this test can be offered within accredited scope depends on your product and the standard applied; since accreditation is method-based, the scope is confirmed in writing at the quotation stage.

Scope and authorisations

Related Regulations

EU 2017/745 Medical Device Regulation (MDR)
Medical Device Regulation (Türkiye)
ISO 14971 (risk management for medical devices)
ISO 13485 (medical devices — quality management system)

Medikal Cihaz Testleri — What Does This Testing Field Cover?

The section below describes the field that the Packaging Validation test belongs to; the conditions and acceptance criteria of this particular test are given in the sections above. The scope specific to your product is confirmed in writing at the quotation stage.

Medical device testing shows that a device is safe for the patient and the user and maintains its intended performance. In this family safety is not only about avoiding harm; a device failing to perform its expected function is also treated as a risk. A monitor missing an alarm or a pump delivering the wrong dose is directly a patient safety event.

At the centre of the field is RISK MANAGEMENT, and this is what sets medical apart from other sectors. The risk management process run under ISO 14971 also determines which tests are required. The test list is not copied from a table of standards; it is derived and justified from the device's intended use, the nature and duration of patient contact, the use environment and foreseeable misuse.

Assessment consists of several separate bodies of work, each with its own set of standards. Biocompatibility runs through the ISO 10993 series, electrical device safety through the IEC 60601 series, sterilisation through ISO 11135/11137/17665, packaging through ISO 11607, software through IEC 62304 and usability through IEC 62366. The quality system (ISO 13485) is the framework that binds these together.

Which tests are required is determined by the device's CLASS and its MODE OF CONTACT WITH THE BODY. A product in brief contact with skin and an implant entering the bloodstream do not go through the same test set; the scope is set by a biological evaluation plan prepared under ISO 10993-1. That plan justifies in writing which endpoints are required and why the others are not.

Packaging and sterilisation are taken as seriously as the device itself in this field. For a sterile device the packaging is not a transport container but the barrier that maintains sterility; if the barrier is breached, the device is no longer sterile. Packaging processes are therefore validated and shelf life is supported by real-time ageing data.

For devices containing software, assessment shifts from testing towards PROCESS assurance. IEC 62304 defines which development and verification steps must be followed according to the safety class of the software; the evidence is the traceability of the development process. Testing software does not make it safe — the process record does.

The clinical side is a separate column of the technical file. Test reports show that the device is technically safe; clinical evaluation establishes that the device delivers the intended clinical benefit and that the benefit-risk balance is acceptable. Neither replaces the other.

Method groups in this field

Biocompatibility
Cytotoxicity, irritation, skin sensitisation, systemic toxicity, haemocompatibility, genotoxicity and local effects after implantation. The required endpoints are set by the ISO 10993-1 plan.
Electrical device safety
IEC 60601-1 basic safety and essential performance; EMC, alarm, usability and environmental requirements through the collateral standards.
Sterilisation validation
Validation of sterilisation processes by ethylene oxide, radiation or moist heat; bioburden and sterility assurance level studies.
Packaging
Integrity of the sterile barrier system, seal strength, distribution simulation and shelf-life studies.
Microbiological tests
Bioburden determination, sterility testing, bacterial endotoxin and, where required, carrier validation studies.
Software and usability
IEC 62304 life cycle evidence and use-error focused evaluation under IEC 62366.

Commonly confused in this field

Cytotoxicity alone is not evidence of biocompatibility; the required set of endpoints is determined and justified according to ISO 10993-1.
An ISO 13485 certificate does not confer CE marking; classification under the MDR, the technical file and the notified body process run separately.
Accelerated ageing does not replace real-time ageing; a shelf life claim is supported by real-time data.
A change of material (supplier, pigment, sterilisation method) may require the biological evaluation to be repeated; it is not a silent change.
An assessment made without the collateral and particular standards for IEC 60601-1 is incomplete; which -1-x and -2-x standards were applied must appear in the report.
In vitro diagnostic devices fall under the IVDR rather than the MDR, and laboratory equipment is often on the IEC 61010-1 side.

Which decisions these results support

MDR/IVDR technical file and notified body assessment
Completing the biological evaluation plan
Sterilisation and packaging validation
Determining shelf life and storage conditions
Determining the scope of reassessment after a design change

Related Tests

Frequently Asked Questions About Packaging Validation — ISO 11607

Is accelerated ageing sufficient on its own?

It is accepted as interim evidence for initial market launch, but ISO 11607 also requires real-time ageing data to be collected. The real-time data must support the accelerated result.

Is higher seal strength always better?

No. An excessively strong seal makes aseptic opening difficult and can cause fibre tear-out on opening. Acceptance is therefore defined as a range.